blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2920175

EP2920175 - TRIAZOLOPYRIDAZINE DERIVATIVES AS BROMODOMAIN INHIBITORS [Right-click to bookmark this link]
Former [2015/39]TRIAZOLOPYRIDAZINE
[2018/43]
StatusNo opposition filed within time limit
Status updated on  30.08.2019
Database last updated on 31.08.2024
FormerThe patent has been granted
Status updated on  21.09.2018
FormerGrant of patent is intended
Status updated on  27.05.2018
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, HU, MK		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2018/43]
Former [2015/39]For all designated states
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
Inventor(s)01 / ENGELHARDT, Harald
BOEHRINGER INGELHEIM GMBH
Corporate Patents
Binger Strasse 173
55216 Ingelheim Am Rhein / DE
02 / SMETHURST, Christian
BOEHRINGER INGELHEIM GMBH
Corporate Patents
Binger Strasse 173
55216 Ingelheim Am Rhein / DE
03 / STEFFEN, Andreas
BOEHRINGER INGELHEIM GMBH
Corporate Patents
Binger Strasse 173
55216 Ingelheim Am Rhein / DE
04 / REISER, Ulrich
BOEHRINGER INGELHEIM GMBH
Corporate Patents
Binger Strasse 173
55216 Ingelheim Am Rhein / DE
05 / KESSLER, Dirk
BOEHRINGER INGELHEIM GMBH
Corporate Patents
Binger Strasse 173
55216 Ingelheim Am Rhein / DE
06 / GIANNI, Davide
BOEHRINGER INGELHEIM GMBH
Corporate Patents
Binger Strasse 173
55216 Ingelheim Am Rhein / DE
 [2015/39]
Representative(s)Simon, Elke Anna Maria, et al
Boehringer Ingelheim GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2015/39]
Application number, filing date13791802.513.11.2013
[2015/39]
WO2013EP73758
Priority number, dateEP2012019245213.11.2012         Original published format: EP 12192452
[2015/39]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014076146
Date:22.05.2014
Language:EN
[2014/21]
Type: A1 Application with search report 
No.:EP2920175
Date:23.09.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 22.05.2014 takes the place of the publication of the European patent application.
[2015/39]
Type: B1 Patent specification 
No.:EP2920175
Date:24.10.2018
Language:EN
[2018/43]
Search report(s)International search report - published on:EP22.05.2014
ClassificationIPC:C07D487/04, A61K31/5025
[2015/39]
CPC:
C07D487/04 (EP,US); A61K31/5025 (EP,US); A61K45/06 (EP,US);
A61P35/00 (EP)
C-Set:
A61K31/5025, A61K2300/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/39]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:TRIAZOLOPYRIDAZINDERIVATE ALS BROMODOMAINHEMMER[2018/43]
English:TRIAZOLOPYRIDAZINE DERIVATIVES AS BROMODOMAIN INHIBITORS[2018/43]
French:DÉRIVÉS DE TRIAZOLOPYRIDAZINE COMME INHIBITEURS DE BROMODOMAINE[2018/43]
Former [2015/39]TRIAZOLPYRIDAZIN
Former [2015/39]TRIAZOLOPYRIDAZINE
Former [2015/39]DÉRIVÉS TRIAZOLOPYRIDAZINES
Entry into regional phase15.06.2015National basic fee paid 
15.06.2015Designation fee(s) paid 
15.06.2015Examination fee paid 
Examination procedure15.06.2015Examination requested  [2015/39]
22.12.2015Amendment by applicant (claims and/or description)
25.02.2016Despatch of a communication from the examining division (Time limit: M04)
05.07.2016Reply to a communication from the examining division
28.05.2018Communication of intention to grant the patent
17.09.2018Fee for grant paid
17.09.2018Fee for publishing/printing paid
17.09.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.02.2016
Opposition(s)25.07.2019No opposition filed within time limit [2019/40]
Fees paidRenewal fee
30.11.2015Renewal fee patent year 03
30.11.2016Renewal fee patent year 04
30.11.2017Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU13.11.2013
AL24.10.2018
AT24.10.2018
CY24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
ES24.10.2018
FI24.10.2018
HR24.10.2018
IT24.10.2018
LT24.10.2018
LV24.10.2018
MC24.10.2018
MK24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SI24.10.2018
SK24.10.2018
SM24.10.2018
TR24.10.2018
IE13.11.2018
LU13.11.2018
MT13.11.2018
BE30.11.2018
CH30.11.2018
LI30.11.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
[2020/31]
Former [2020/17]AL24.10.2018
AT24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
ES24.10.2018
FI24.10.2018
HR24.10.2018
IT24.10.2018
LT24.10.2018
LV24.10.2018
MC24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SI24.10.2018
SK24.10.2018
SM24.10.2018
TR24.10.2018
IE13.11.2018
LU13.11.2018
MT13.11.2018
BE30.11.2018
CH30.11.2018
LI30.11.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2020/08]AL24.10.2018
AT24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
ES24.10.2018
FI24.10.2018
HR24.10.2018
IT24.10.2018
LT24.10.2018
LV24.10.2018
MC24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SI24.10.2018
SK24.10.2018
SM24.10.2018
IE13.11.2018
LU13.11.2018
MT13.11.2018
BE30.11.2018
CH30.11.2018
LI30.11.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/50]AL24.10.2018
AT24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
ES24.10.2018
FI24.10.2018
HR24.10.2018
IT24.10.2018
LT24.10.2018
LV24.10.2018
MC24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SI24.10.2018
SK24.10.2018
SM24.10.2018
IE13.11.2018
LU13.11.2018
BE30.11.2018
CH30.11.2018
LI30.11.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/48]AL24.10.2018
AT24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
ES24.10.2018
FI24.10.2018
HR24.10.2018
IT24.10.2018
LT24.10.2018
LV24.10.2018
MC24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SK24.10.2018
SM24.10.2018
IE13.11.2018
LU13.11.2018
CH30.11.2018
LI30.11.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/40]AL24.10.2018
AT24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
ES24.10.2018
FI24.10.2018
HR24.10.2018
IT24.10.2018
LT24.10.2018
LV24.10.2018
MC24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SK24.10.2018
SM24.10.2018
LU13.11.2018
CH30.11.2018
LI30.11.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/37]AL24.10.2018
AT24.10.2018
CZ24.10.2018
DK24.10.2018
EE24.10.2018
ES24.10.2018
FI24.10.2018
HR24.10.2018
IT24.10.2018
LT24.10.2018
LV24.10.2018
MC24.10.2018
NL24.10.2018
PL24.10.2018
RO24.10.2018
RS24.10.2018
SE24.10.2018
SM24.10.2018
LU13.11.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/35]AL24.10.2018
AT24.10.2018
CZ24.10.2018
DK24.10.2018
ES24.10.2018
FI24.10.2018
HR24.10.2018
IT24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
RS24.10.2018
SE24.10.2018
LU13.11.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/34]AL24.10.2018
AT24.10.2018
DK24.10.2018
ES24.10.2018
FI24.10.2018
HR24.10.2018
IT24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
RS24.10.2018
SE24.10.2018
LU13.11.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/26]AL24.10.2018
AT24.10.2018
ES24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
RS24.10.2018
SE24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
PT24.02.2019
Former [2019/25]AT24.10.2018
ES24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
RS24.10.2018
SE24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
Former [2019/24]AT24.10.2018
ES24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
SE24.10.2018
BG24.01.2019
NO24.01.2019
GR25.01.2019
IS24.02.2019
Former [2019/23]AT24.10.2018
ES24.10.2018
FI24.10.2018
HR24.10.2018
LT24.10.2018
LV24.10.2018
NL24.10.2018
PL24.10.2018
BG24.01.2019
NO24.01.2019
IS24.02.2019
Former [2019/22]FI24.10.2018
LT24.10.2018
NL24.10.2018
PL24.10.2018
BG24.01.2019
NO24.01.2019
IS24.02.2019
Former [2019/21]FI24.10.2018
LT24.10.2018
NL24.10.2018
NO24.01.2019
IS24.02.2019
Former [2019/20]LT24.10.2018
NL24.10.2018
NO24.01.2019
Former [2019/17]NL24.10.2018
Cited inInternational search[A]GB1480621  (LEPETIT SPA) [A] 1* page 1 to page 2, column 2, line 19;; claim 1 *;
 [A]WO2007075567  (JANSSEN PHARMACEUTICA NV [BE], et al) [A] 1-26 * claims 1,13,16-19 *;
 [A]WO2008109104  (UNIV CALIFORNIA [US], et al) [A] 1-26 * claims 1-39 *;
 [A]WO2011161031  (GLAXOSMITHKLINE LLC [US], et al) [A] 1-26 * claims 1,29-33,35-37,39 *;
 [XP]WO2012174487  (CONSTELLATION PHARMACEUTICALS INC [US], et al) [XP] 1,2,10,20-26 * claims 1,2,5,6,20-30,32,33 *;
 [X]  - KATRUSIAK, ANNA ET AL., "Nucleophilic substitution and lipophilicity-structure relations in methylazolopyridazines", COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS., CZINSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY, PRAGUE., (2005), vol. 70, no. 9, ISSN 0010-0765, pages 1372 - 1386, XP008160516 [X] 1,2,10 * page 1376, compound 18; page 1385, lines 3 to 6 *

DOI:   http://dx.doi.org/10.1135/cccc20051372
by applicantWO2011054553
 WO2011054846
    - YANG; ZHOU, MOL. CELL. BIOL., (2008), vol. 28, page 967
    - FRENCH ET AL., CANCER RES., (2003), vol. 63, page 304
    - ZUBER ET AL., NATURE, (2011), vol. 478, no. 7370, pages 524 - 8
    - LEROY, MOL. CELL, (2008), vol. 30, no. 1, pages 51 - 60
    - BIRGE, S.M. ET AL., J. PHARM. SCI., (1977), vol. 66, pages 1 - 19
    - TETRAHYDRON LETTERS, (2003), vol. 44, pages 41 - 43
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.